More Info: Chart | Historical Prices | Profile | Reports | Research | Insider | Industry | Options
Research Abstract - Endocyte, Inc. (ecyt)
Resources
· Report Screener
· Stock Screener
· Research by Industry
· Earnings Dates
· Up/Downgrades
Summary
Symbol(s): ECYT
Date:  12-Apr-14
Author: Hunter Orr
Contributor: Alpha Street Research
Title: ECYT - Endocyte Inc - Downgraded to a Sell - Company Analysis and ASR Ranking Report
Document Size:  9 pages
Price:  $24
Document Type:  Adobe Acrobat Reader®
Download free Adobe Acrobat Reader®
Research Reports Premium Services
· Get the full report for $24.
· You will have access to this report for 24 hours.
Preview: Next 4
Synopsis
www.AlphaStreetResearch.com - Full Coverage of 3,000 U.S. equities. Reports include Financials, Ratios, Competitor Comparison, and our proprietary ASR Ranking indicating Buy/Sell/Hold. Endocyte Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The Company uses a proprietary technology to create small molecule drug conjugates, or SMDCs, and companion imaging diagnostics that actively target receptors that are over-expressed on...



Copyright © 2009 Yahoo Inc. All rights reserved.Privacy Policy - Terms of Service
To learn more about Yahoo's use of personal information, please read the Privacy Policy

Company information © 2005 Reuters. All Rights Reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
See our Important Disclaimers and Legal Information.